

Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) - Pipeline Review, H2 2018

<https://marketpublishers.com/r/D42A370C841EN.html>

Date: October 2018

Pages: 29

Price: US\$ 3,500.00 (Single User License)

ID: D42A370C841EN

Abstracts

Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) - Pipeline Review, H2 2018

SUMMARY

According to the recently published report 'Diacylglycerol O Acyltransferase 1 - Pipeline Review, H2 2018'; Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) pipeline Target constitutes close to 5 molecules. Out of which approximately 4 molecules are developed by companies and remaining by the universities/institutes.

Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) - Diglyceride acyltransferase 1 (DGAT-1) is an enzyme that catalyzes the formation of triglycerides from diacylglycerol and Acyl-CoA. It plays a role in esterifying exogenous fatty acids to glycerol. It functions as the major acyl-CoA retinol acyltransferase (ARAT) in the skin, where it acts to maintain retinoid homeostasis and prevent retinoid toxicity leading to skin and hair disorders.

The report 'Diacylglycerol O Acyltransferase 1 - Pipeline Review, H2 2018' outlays comprehensive information on the Diacylglycerol O Acyltransferase 1 (Diglyceride

Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) targeted therapeutics development with respective active and dormant or discontinued projects.

Currently, The molecules developed by companies in Phase I and Preclinical stages are 3 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Dermatology, Metabolic Disorders, Gastrointestinal and Immunology which include indications Acne Vulgaris, Dyslipidemia, Hyperlipidemia, Inflammation, Non-Alcoholic Steatohepatitis (NASH) and Obesity.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the global therapeutic landscape for Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20)

The report reviews Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and

collaboration details & other developmental activities

The report reviews key players involved in Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) targeted therapeutics and enlists all their major and minor projects

The report assesses Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) targeted therapeutics

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading

companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction

Global Markets Direct Report Coverage

Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) - Overview

Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) - Companies Involved in Therapeutics Development

Boston Pharmaceuticals Inc

Viking Therapeutics Inc

Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) - Drug Profiles

BOS-356 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RVT-503 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit DGAT1 for Hyperlipidemia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit DGAT-1 for Inflammation and Metabolic Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SNP-630 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) - Dormant Products

Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) - Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Boston Pharmaceuticals Inc, H2 2018
Pipeline by Viking Therapeutics Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Discontinued Products, H2 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

COMPANIES MENTIONED

Boston Pharmaceuticals Inc

Viking Therapeutics Inc

I would like to order

Product name: Diacylglycerol O Acyltransferase 1 (Diglyceride Acyltransferase 1 or ACAT Related Gene Product 1 or Acyl CoA Retinol O Fatty Acyltransferase or DGAT1 or EC 2.3.1.76 or EC 2.3.1.20) - Pipeline Review, H2 2018

Product link: <https://marketpublishers.com/r/D42A370C841EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/D42A370C841EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970